Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

NCT ID: NCT01841684

Last Updated: 2015-06-01

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-06-30
• Study Completion Date: 2014-06-30

Brief Summary

This study will evaluate the safety and effect of anacetrapib on low-density lipoprotein-cholesterol (LDL-C) when added to ongoing lipid-lowering therapy. The primary hypothesis is that treatment with anacetrapib 100 mg for 12 weeks will lower LDL-C to a greater extent than treatment with placebo.

Conditions

Hyperlipoproteinemia Type II; Homozygous Familial Hypercholesterolemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Anacetrapib

Participants receive anacetrapib 100 mg orally once daily for 12 weeks.

Group Type: EXPERIMENTAL

Anacetrapib

Intervention Type: DRUG

100 mg tablet orally, once daily for 12 weeks

Placebo

Participants receive placebo orally once daily for 12 weeks.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo for anacetrapib orally, once daily for 12 weeks

Interventions

Anacetrapib

100 mg tablet orally, once daily for 12 weeks

Intervention Type: DRUG

Placebo

Placebo for anacetrapib orally, once daily for 12 weeks

Intervention Type: DRUG

Other Intervention Names

MK-0859

Eligibility Criteria

Inclusion Criteria

• Diagnosed with HoFH by genotyping
• If female, cannot be of reproductive potential
• Have been stabilized on statin monotherapy or statin therapy coadministered

with other lipid medications for at least 6 weeks

Exclusion Criteria

• Severe chronic heart failure defined by New York Heart Association

(NYHA) Classes III or IV

• Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary arterial by-pass graft (CABG), unstable angina or stroke within 3 months prior to Visit 1 or has planned procedures scheduled within first 12 weeks of study
• Uncontrolled endocrine or metabolic disease known to influence serum

lipids or lipoproteins

• Active or chronic hepatobiliary or gall bladder disease
• History of ileal bypass, gastric bypass, or other significant condition

associated with malabsorption

• Human immunodeficiency virus (HIV) positive
• Donated blood products or has had phlebotomy of >300 mL within 8 weeks or intends to donate 250_mL of blood products or receive blood products within the projected duration of the study
• Taking medications that are potent inhibitors or inducers of cytochrome P450 3A4 (CYP3A4), including but not limited to cyclosporine, systemic itraconazole or ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St John's wort) or has discontinued treatment <3 weeks prior. Consumption of >1 liter of grapefruit juice per day is also prohibited.
• Currently participating or has participated in a study with an investigational compound or device within 3 months
• Consume more than 2 alcoholic drinks per day
• Receiving treatment with systemic corticosteroids or systemic anabolic agents

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

2012-002434-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

0859-042

Identifier Type: -

Identifier Source: org_study_id